Treatment of heart failure with preserved ejection fraction

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Heart failure with preserved ejection fraction (HFpEF) is a major public health problem in the United States. However, in contrast to systolic heart failure, there are little data to guide treatment decisions in HFpEF, and no therapies have been shown to improve outcome in these patients. This review explores what is currently known about the pathophysiologic mechanisms causing HFpEF in order to frame appropriate therapeutic targets and better understand the clinical responses commonly observed in patients with HFpEF. Data from published clinical trials are reviewed, and the roles for each class of drug commonly used in practice are examined. Finally, novel therapies and future directions for basic investigation and clinical trials are discussed.

Original languageEnglish (US)
Pages (from-to)79-87
Number of pages9
JournalCurrent Treatment Options in Cardiovascular Medicine
Volume11
Issue number1
DOIs
StatePublished - 2009

Fingerprint

Treatment Failure
Heart Failure
Clinical Trials
Systolic Heart Failure
Therapeutics
Public Health
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Treatment of heart failure with preserved ejection fraction. / Borlaug, Barry A.

In: Current Treatment Options in Cardiovascular Medicine, Vol. 11, No. 1, 2009, p. 79-87.

Research output: Contribution to journalArticle

@article{31263d7d4f6d41d1b7efb559c2303f05,
title = "Treatment of heart failure with preserved ejection fraction",
abstract = "Heart failure with preserved ejection fraction (HFpEF) is a major public health problem in the United States. However, in contrast to systolic heart failure, there are little data to guide treatment decisions in HFpEF, and no therapies have been shown to improve outcome in these patients. This review explores what is currently known about the pathophysiologic mechanisms causing HFpEF in order to frame appropriate therapeutic targets and better understand the clinical responses commonly observed in patients with HFpEF. Data from published clinical trials are reviewed, and the roles for each class of drug commonly used in practice are examined. Finally, novel therapies and future directions for basic investigation and clinical trials are discussed.",
author = "Borlaug, {Barry A}",
year = "2009",
doi = "10.1007/s11936-009-0009-5",
language = "English (US)",
volume = "11",
pages = "79--87",
journal = "Current Treatment Options in Cardiovascular Medicine",
issn = "1092-8464",
publisher = "Current Science, Inc.",
number = "1",

}

TY - JOUR

T1 - Treatment of heart failure with preserved ejection fraction

AU - Borlaug, Barry A

PY - 2009

Y1 - 2009

N2 - Heart failure with preserved ejection fraction (HFpEF) is a major public health problem in the United States. However, in contrast to systolic heart failure, there are little data to guide treatment decisions in HFpEF, and no therapies have been shown to improve outcome in these patients. This review explores what is currently known about the pathophysiologic mechanisms causing HFpEF in order to frame appropriate therapeutic targets and better understand the clinical responses commonly observed in patients with HFpEF. Data from published clinical trials are reviewed, and the roles for each class of drug commonly used in practice are examined. Finally, novel therapies and future directions for basic investigation and clinical trials are discussed.

AB - Heart failure with preserved ejection fraction (HFpEF) is a major public health problem in the United States. However, in contrast to systolic heart failure, there are little data to guide treatment decisions in HFpEF, and no therapies have been shown to improve outcome in these patients. This review explores what is currently known about the pathophysiologic mechanisms causing HFpEF in order to frame appropriate therapeutic targets and better understand the clinical responses commonly observed in patients with HFpEF. Data from published clinical trials are reviewed, and the roles for each class of drug commonly used in practice are examined. Finally, novel therapies and future directions for basic investigation and clinical trials are discussed.

UR - http://www.scopus.com/inward/record.url?scp=58649109169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58649109169&partnerID=8YFLogxK

U2 - 10.1007/s11936-009-0009-5

DO - 10.1007/s11936-009-0009-5

M3 - Article

C2 - 19141264

AN - SCOPUS:58649109169

VL - 11

SP - 79

EP - 87

JO - Current Treatment Options in Cardiovascular Medicine

JF - Current Treatment Options in Cardiovascular Medicine

SN - 1092-8464

IS - 1

ER -